Related Experiment Videos
[Mortality in schizophrenic patients. 3 years follow-up of a cohort]
1INSERM XR-302, Le Vésinet.
Unlabelled:
Although schizophrenia is not in itself a lethal illness, an overmortality in psychiatric patients in comparison to the reference population has been attested to for a long time. Until the use of antibiotics, this overmortality was mainly due to infectious diseases caused by the close quarters in mental institutions. At the present time this overmortality is mainly due to suicide but also with a noteworthy mortality by certain natural causes such as respiratory diseases and cardio-vascular and cerebro-vascular diseases. Some questions still persist as far as cancer is concerned because it represents the cause of death for which the results are the most contradictory and the most surprising. In France psychiatric case registers do not exist. At this moment, there is no systematic registration which allows us to study the mortality of psychiatric patients. If we want to know about the mortality of the mentally ill, we have to conduct special research. Consequently, a special research project concerning the mortality of schizophrenic patients taken into care in public psychiatric sectors was undertaken in 1993. We chose schizophrenic patients because of the greater reliability of the diagnosis and because they are a population affected by over-mortality, particularly by suicide. The importance of mortality studies remains twofold:--They are a good indicator of the quality of health care policy as is for instance the infant mortality rate which remains one of the best indicators of the quality of maternal and infant health care.--They enable the formulation of research hypotheses to be made if you point out specific causes of death in a sub-group like schizophrenics compared to the general population. METHOLOGY: The setting of the research was the public psychiatric sector. Public psychiatric sector is a geographical catchment area of about 70,000 adult inhabitants. The national territory is divided into 800 psychiatric sectors. Sectors volunteered to participate. A selection at random would have led to too many refusal to be pertinent. The sectors were contacted through associations like the French Epidemiologic Psychiatric Group, professional reviews, and telephone contacts. Sectors volunteered to participate but patients had to be included at random. All the patients seen within three months and who met the following inclusion criteria: schizophrenic (ICD10) seen as in-or-out patients, aged 18-64, residing in France and under care in public psychiatric sectors were eligible. Various observations concerning social and demographic characteristics, behavioural risks, physical health, access to private somatic care and psychotropic medication were been made by means of a questionnaire at the time of inclusion. Because we wanted to compare the access to private somatic care, one of the themes studied, consequently we excluded chronic patients, that is to say patients hospitalized for more than one year without interruption and whose access to private somatic care couldn't be comparable in a pertinent way to the general population access.
Follow-Up:
every year at the anniversary of the inclusion of the patient we ask the sector if the patient is alive, dead or lost sight of. In the last two cases we send a letter to the City hall of their place of birth (procedure approved by National Commission for Informatics and Freedom) in order to know if they are alive or not and if they are dead to know the date of their death. For patients deceased we check then their causes of death in the French National Register of Deaths. For deceased patients we check also their causes of death near the sector. So we have a twofold means of checking up.
Results:
3,470 patients were included. These patients came from 122 sectors (15% of all the sectors) spread out over 73% of the territory. The sample did not present statistical differences in its sex and age distribution compared to a national sample. A longitudinal observation has been going on for thre
Insights
This study investigated mortality rates in schizophrenic patients in France. Findings highlight significant overmortality compared to the general population, particularly from suicide and certain natural causes.
Area of Science:
- Psychiatry
- Epidemiology
- Public Health
Background:
- Schizophrenia patients experience higher mortality rates than the general population.
- Historically, infectious diseases contributed to this overmortality; currently, suicide and natural causes are primary factors.
- Cancer mortality in this group remains a complex and debated topic.
Purpose of the Study:
- To investigate mortality patterns in schizophrenic patients under public psychiatric care in France.
- To establish a baseline for mortality studies in the absence of national psychiatric case registers.
- To inform health care policy and generate research hypotheses regarding specific causes of death.
Main Methods:
- A prospective study was conducted in French public psychiatric sectors (n=122) from 1993.
- Inclusion criteria: schizophrenic patients (ICD10), aged 18-64, under public psychiatric care.
- Data collected: demographics, behavioral risks, physical health, healthcare access, and medication. Excluded chronic patients for comparable somatic care access.
Main Results:
- 3,470 schizophrenic patients were included, representing 15% of all sectors across 73% of French territory.
- The patient sample's sex and age distribution mirrored the national sample.
- Longitudinal observation data collection was ongoing.
Conclusions:
- Mortality studies are crucial indicators of healthcare quality and policy effectiveness.
- Identifying specific mortality causes in schizophrenic patients can guide future research and interventions.
- This research establishes a framework for studying psychiatric patient mortality in France.